Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
Titel:
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
Auteur:
Jhaveri, K.L. Wang, X.V. Makker, V. Luoh, S.-W. Mitchell, E.P. Zwiebel, J.A. Sharon, E. Gray, R.J. Li, S. McShane, L.M. Rubinstein, L.V. Patton, D. Williams, P.M. Hamilton, S.R. Conley, B.A. Arteaga, C.L. Harris, L.N. O’Dwyer, P.J. Chen, A.P. Flaherty, K.T.